Vincent A. Mukkada, MD
- Medical Director, Lumen Inpatient Unit
- Interim Medical Director, Division of Gastroenterology, Hepatology, and Nutrition
- Medical Director, A4S
- Professor, UC Department of Pediatrics
- vincent.mukkada@cchmc.org
- Board Certified
About
Biography
I specialize in patient care and research related to pediatric gastroenterology — specifically, eosinophilic gastrointestinal (GI) disease and pediatric feeding disorders. The research I pursue is primarily influenced by the health issues that I see every day in the patients who have eosinophilic GI disease and pediatric feeding disorders. I have also become the medical director of our inpatient gastroenterology floor, where we work to continuously improve the quality of care we provide to our patients.
My colleagues and I are working to improve clinical care and monitoring of pediatric patients with eosinophilic disease. We want to better understand the causes and risk factors associated with developing complications in eosinophilic esophagitis. In addition, we are looking to improve the characterization and treatment of feeding problems found in patients with food allergic conditions.
A pediatric feeding disorder is impaired oral intake that is not age-appropriate and can be associated with medical, nutritional, feeding skill and/or psychosocial dysfunction. Continued research into the pathogenesis and best treatment approaches is essential to help children with these disorders.
I was inspired to become a healthcare provider due to my family’s involvement in the healthcare field. My mother is a physician and my father is an academic scientist with a Ph.D. in microbiology. Healthcare and biology surrounded me as I was growing up. While I first resisted following this path, I soon realized that this was the right fit for my career. I was influenced by several inspiring mentors who first encouraged me to enter pediatric gastroenterology and then drew me to study eosinophilic diseases.
In 2010, I was awarded a national Junior Faculty research award from the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. In addition, I achieved the highest patient satisfaction score for the first quarter of 2019 from the Department of Pediatrics at Cincinnati Children’s Hospital Medical Center. My research has been published in numerous manuscripts in journals, including the Journal of Allergy and Clinical Immunology, Journal of Clinical Investigation, Gastroenterology and Genes and Immunity.
BA: University of Pennsylvania, Philadelphia, PA, 1998.
MD: University of Cincinnati, Cincinnati, OH, 2002.
Residency: Pediatrics, Brown University / Hasbro Children’s Hospital, Providence, RI, 2002-2005.
Fellowship: Pediatric Gastroenterology, University of Colorado / Children’s Hospital of Colorado, Denver, CO, 2005-2008.
Research Scholar: University of Colorado / Children’s Hospital of Colorado, Denver, CO, 2008-2009.
Certifications: General Pediatrics, 2005; Pediatric Gastroenterology, 2009.
Interests
Eosinophilic gastrointestinal disorders; pediatric feeding problems
Services and Specialties
Interests
Eosinophilic gastrointestinal disorders; pediatric feeding problems
Research Areas
Locations (2)
Insurance Information
Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.
Publications
One-food versus 4-food elimination diet for pediatric eosinophilic esophagitis: A multisite randomized trial. Journal of Allergy and Clinical Immunology. 2025; 155:S0091-6749(24)00907-2.
Budesonide Oral Suspension: Expanding the Toolkit for Eosinophilic Esophagitis. The American Journal of Gastroenterology (Elsevier). 2025; 120:16-19.
EFFECT OF CORTICOSTEROID USE ON OUTCOMES IN PATIENTS WITH EOSINOPHILIC ESOPHAGITIS RECEIVING BUDESONIDE ORAL SUSPENSION. Annals of Allergy, Asthma, and Immunology. 2024; 133:s80.
EFFECT OF BUDESONIDE ORAL SUSPENSION ON DYSPHAGIA SEVERITY OUTCOMES IN PATIENTS WITH EOSINOPHILIC ESOPHAGITIS. Annals of Allergy, Asthma, and Immunology. 2024; 133:s79-s80.
Induction of sustained remission and reversal of pathologic transcriptome achieved with tezepelumab in an adolescent with eosinophilic esophagitis. The Journal of Allergy and Clinical Immunology: in Practice. 2024; 12:3147-3149.e2.
TH2 cell compensatory effect following benralizumab treatment for eosinophilic gastritis. Journal of Allergy and Clinical Immunology. 2024; 154:1325-1332.e2.
S693 Effect of Budesonide Oral Suspension on Dysphagia Symptom Resolution and Time to First Dysphagia Symptom Response in Eosinophilic Esophagitis: Post Hoc Analysis of Phase 2 and Phase 3 Placebo-Controlled Trials. The American Journal of Gastroenterology (Elsevier). 2024; 119:s480.
S692 Effect of Budesonide Oral Suspension on Dysphagia Symptom Outcomes in Patients With Eosinophilic Esophagitis: A Pooled Post Hoc Analysis of Data From a Phase 2 and a Phase 3 Trial. The American Journal of Gastroenterology (Elsevier). 2024; 119:s479-s480.
Losartan Treatment Reduces Esophageal Eosinophilic Inflammation in a Subset of Eosinophilic Esophagitis. The Journal of Allergy and Clinical Immunology: in Practice. 2024; 12:2427-2438.e3.
Manometric findings in children with eosinophilic esophagitis and persistent post-remission dysphagia. 2024; 5:289-295.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
© 1999-2025 Cincinnati Children's Hospital Medical Center. All rights reserved.
Patient Ratings and Comments
All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent experience management company, Qualtrics. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey